These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38978570)

  • 21. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
    Wadhwa A; Wang S; Patiño-Escobar B; Bidkar AP; Bobba KN; Chan E; Meher N; Bidlingmaier S; Su Y; Dhrona S; Geng H; Sarin V; VanBrocklin HF; Wilson DM; He J; Zhang L; Steri V; Wong SW; Martin TG; Seo Y; Liu B; Wiita AP; Flavell RR
    Clin Cancer Res; 2024 Mar; 30(5):1009-1021. PubMed ID: 38109209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer.
    Park JY; Chae JR; Cho YL; Kim Y; Lee D; Lee JK; Kang WJ
    Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33080969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.
    Grega SD; Zheng DX; Zheng QH
    Am J Nucl Med Mol Imaging; 2022; 12(4):113-121. PubMed ID: 36072763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
    Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
    Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
    Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
    World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
    Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
    ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
    Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
    Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with
    Watabe T; Kabayama K; Naka S; Yamamoto R; Kaneda K; Serada S; Ooe K; Toyoshima A; Wang Y; Haba H; Kurimoto K; Kobayashi T; Shimosegawa E; Tomiyama N; Fukase K; Naka T
    J Nucl Med; 2023 Dec; 64(12):1949-1955. PubMed ID: 37827841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
    Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
    Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
    de Lucas AG; Schuhmacher AJ; Oteo M; Romero E; Cámara JA; de Martino A; Arroyo AG; Morcillo MÁ; Squatrito M; Martinez-Torrecuadrada JL; Mulero F
    PLoS One; 2016; 11(7):e0158634. PubMed ID: 27462980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
    Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressing hepatocellular carcinoma.
    Habibollahi P; Gurevich A; Hui JZ; Weinfurtner K; McClung G; Adler J; Soulen MC; Kaplan DE; Nadolski GJ; Hunt SJ; Tsourkas A; Gade TP
    Mol Cancer Ther; 2024 Sep; ():. PubMed ID: 39312187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
    Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
    Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
    Front Immunol; 2022; 13():963031. PubMed ID: 36059488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.